Valeant needs some painkillers after a Monday to forget
Beleaguered drugmaker Valeant Pharmaceuticals – one of the most widely-held names in the CLO market – was subject to yet more unwanted headlines yesterday
Related Stories
- Strong run helps CLOs shrug off Altice downgrade 9 days ago
- US loan volume nears record levels 9 days ago
- Credit hedge funds 9 days ago
- Relative to Airbus, Boeing was long accountants but short engineers 9 days ago
- IACPM survey finds credit PMs still gloomy, but less so than last quarter 15 days ago
CLOs
- Middle market portfolios aren't immune to rate stress, according to new research 1 day ago
- Sona prices CLO number two 1 day ago
- Another 2016 vintage CLO gets reset as Octagon stays busy 1 day ago
- Neuberger Berman resets 2016 vintage for second time 1 day ago
- Beach Point brings in tight price for third US CLO 1 day ago